Αποτελέσματα Αναζήτησης
1 Απρ 2022 · The purpose of the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” (2022 HF guideline) is to provide an update and to consolidate the “2013 ACCF/AHA Guideline for the Management of Heart Failure” 1 for adults and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure ...
- 2022 Aha/Acc/Hfsa Guideline for The
The webpage provides access to AHA/ASA journals on...
- 2022 Aha/Acc/Hfsa Guideline for The
1 Απρ 2022 · TOP 10 TAKE-HOME MESSAGES. Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose cotransporter-2 inhibitors (SGLT2i).
1 Απρ 2022 · Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients.
The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests.
14 Φεβ 2020 · SGLT2i (Sodium-glucose co-transporter 2 inhibitors), initially developed for their glucose-lowering potential by blocking renal tubular glucose reabsorption, have been shown to decrease heart failure (HF) events by 27% to 39% in high-risk patients with type 2 diabetes mellitus (T2DM) in 3 cardiovascular outcomes trials 1 and a renal outcomes trial.
Use this tool to reference guideline-directed medical therapy (GDMT) across the four ACC/AHA stages of Heart Failure (HF) as outlined in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. See the guideline for specific patient population criteria.
29 Μαρ 2022 · SGLT2 inhibitors (SGLT2i) are now recommended for people with symptomatic chronic HFrEF regardless of the presence or absence of type 2 diabetes. "After careful evaluation of new evidence, guideline-directed medical therapy now includes four medication classes that include SGLT2 inhibitors.
